SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Drug Development
Large-Scale Study Finds One-Third of COVID-19 Patients Suffer Neurological Damage
Six months after a COVID-19 diagnosis, more than 33% of people exhibited some form of brain damage, according to a study appearing in Lancet Psychiatry.
April 12, 2021
 · 
4 min read
 · 
Gail Dutton
Business
Mission Bio Announces New CEO to Manage a “Perfect Storm” for Accelerated Growth
She succeeds Mission Bio’s current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.
April 8, 2021
 · 
5 min read
 · 
Gail Dutton
eDNA from Air Yields Data for Social Distancing, Disease Transmission and More
The technology also has intriguing potential in DNA forensics, even without the presence of other physical samples.
April 8, 2021
 · 
4 min read
 · 
Gail Dutton
TrialJectory IDs Barriers to Oncology Clinical Trial Enrollment, Improving Trial Design
Insights into barriers that cause cancer patients not to enroll in specific trials are helping pharmaceutical companies adjust their trial designs and assumptions.
April 7, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
IDbyDNA’s Metagenomics Suite Future-Proofs Labs for Coming Pathogen Crises
IDbyDNA’s metagenomic approach to viral strain identification combines very sensitive detection with next-gen sequencing to identify emerging and mutant viruses much sooner than either genomic or surveillance methods alone.
April 6, 2021
 · 
4 min read
 · 
Gail Dutton
Igor Golovniov/SOPA Images/LightRocket via Getty
Business
Valence Discovery Deal Brings Purpose-Built AI/ML to Charles River Labs’ Clients
Valence Discovery just announced a strategic alliance with Charles River Laboratories to make its artificial intelligence (AI) and machine learning (ML) platform available to Charles River’s clients.
April 6, 2021
 · 
4 min read
 · 
Gail Dutton
New researches on probable cure for HIV approachin
Heightened Hope For A Cure For HIV, With Research Reaching Inflection Point
Recent advances are giving researchers hope that a functional cure for HIV or possibly even complete eradication of the virus is possible.
April 5, 2021
 · 
5 min read
 · 
Gail Dutton
Policy
Sepsis: Standard of Care Fails While Novel Meds and Diagnostics Go Unused
Sepsis is among the best-known and least effectively treated conditions in the modern world. The standard of care has failed for these infections, leaving the U.S. healthcare system with $62 billion and 270,000 deaths annually. Globally, 11 million die from sepsis each year. Effective drugs and diagnostics are available. They’re just not used.
April 2, 2021
 · 
5 min read
 · 
Gail Dutton
OnQuality’s newly-appointed CEO Michael McCullar.
Business
OnQuality Pharma Raises $20 Million to Support Ongoing Oncodermatology Trial
The trial assesses the safety and efficacy of a targeted supportive care agent that addresses the specific side effects of vascular endothelial growth factor receptor (VEGFR) inhibitors among cancer patients.
March 31, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
Global Vaccine Passports Edge Closer, Speeding Arrival of the Next “Normal”
Vaccine passports are an interim step that can speed the return of some semblance of normality by allowing the rapidly growing numbers of vaccinated people to travel more easily and to attend typically crowded sporting events, concerts and religious services.
March 30, 2021
 · 
5 min read
 · 
Gail Dutton
Drug Development
Meissa’s Nasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses
Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March.
March 25, 2021
 · 
4 min read
 · 
Gail Dutton
C-Suite Execs: Revenue Management Prospects Grow, but Modernization is Needed
Opportunities to optimize the revenue activities that maximize growth will continue to be abundant in 2021, as organizations deploy technology to gain granular insights. None-the-less, modernization is needed.
March 24, 2021
 · 
4 min read
 · 
Gail Dutton
Policy
4 Strategies to Harden the Pharma Supply Chain Before Federal Mandates Kick In
Change is coming to the pharmaceutical supply chain. The supply chain review ordered by President Biden virtually guarantees it with its attempts to understand and improve issues related to supply chain transparency, security and overreliance on a few suppliers in a few regions.
March 23, 2021
 · 
5 min read
 · 
Gail Dutton
Drug Development
Rokote Lab’s COVID-19 Nasal Vaccine on Financing Fence Before Phase I Trials
A COVID-19 nasal spray vaccine developed by Rokote Laboratories Finland Ltd., is preparing for Phase I trials in Finland…if it can win funding.
March 19, 2021
 · 
4 min read
 · 
Gail Dutton
There's a new potential biomarker to determine the
Business
European Genetic Variants are Poor Predictors of Disease in the Middle East
European genetic studies aren’t particularly accurate when applied to Middle East populations, according to new research from the Qatar Foundation.
March 18, 2021
 · 
4 min read
 · 
Gail Dutton
Load More